Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
ChemMedChem · 17.06.2024 · 19 (12)
DOI: 10.1002/cmdc.202300343 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 03.05.2024. Verfasst von Tyler S Beyett und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA, 450 Brookline Avenue, LC4313. Hauptthemen laut MEDLINE: ErbB Receptors, Protein Kinase Inhibitors, Macrocyclic Compounds. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences of the NIH, Ruth L. Kirschstein National Research Service Award.
Abstract (Originalsprache)
A novel macrocyclic inhibitor of mutant EGFR ( BI‐4020 ) has shown promise in pre‐clinical studies of T790M and C797S drug‐resistant non‐small cell lung cancer. To better understand the molecular basis for BI‐4020 selectivity and potency, we have carried out biochemical activity assays and structural analysis with X‐ray crystallography. Biochemical potencies agree with previous studies indicating that BI‐4020 is uniquely potent against drug‐resistant L858R/T790M and L858R/T790M/C797S variants. X‐ray structures with wild‐type (2.4 Å) and T790M/V948R (3.1 Å) EGFR kinase domains show that BI‐4020 is likely rendered selective due to interactions with the kinase domain hinge region as well as T790M, akin to Osimertinib. Additionally, BI‐4020 is also rendered more potent due to its constrained macrocycle geometry as well as additional H‐bonds to conserved K745 and T845 residues in both active and inactive conformations. These findings taken together show how this novel macrocyclic inhibitor is both highly potent and selective for mutant EGFR in a reversible mechanism and motivate structure‐inspired approaches to developing targeted therapies in medicinal oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA, 450 Brookline Avenue, LC4313.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
- Department of Chemistry, University at Buffalo, Buffalo, NY 14260, USA.
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
ORCID-Profile: Tyler S Beyett, David E Heppner, Michael J Eck
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences of the NIH
- Ruth L. Kirschstein National Research Service Award
- NIH-ORIP HEI grant
- Northeastern Collaborative Access Team beamlines
- Nathanael Gray
- NIGMS NIH HHS
- NIH HHS
Zitieren
APA
Beyett, T. S., Rana, J. K., Schaeffner, I. K., Heppner, D. E., & Eck, M. J. (2024). Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase. ChemMedChem, 19(12). https://doi.org/10.1002/cmdc.202300343
Vancouver
Beyett TS, Rana JK, Schaeffner IK, Heppner DE, Eck MJ. Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase. ChemMedChem. 2024;19(12). doi:10.1002/cmdc.202300343
BibTeX
@article{Beyett2024,
author = {Beyett, Tyler S and Rana, Jaimin K and Schaeffner, Ilse K and Heppner, David E and Eck, Michael J},
title = {Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase},
journal = {ChemMedChem},
year = {2024},
volume = {19},
number = {12},
doi = {10.1002/cmdc.202300343}
}
EUVIMED